Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Six years after his diagnosis with chronic lymphocytic leukemia, Jeff Neurman blogs and cohosts a podcast for men with cancer.
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
Starting palliative interventions at the onset of hospitalization for chemotherapy greatly improves quality of life.
Imbruvica plus Rituxan delayed disease progression when compared with a triple chemotherapy regimen.
“With BAX, we have a single target for blocking both types of cell death stemming from the use of doxorubicin."
Some helpful websites to to look up if you or one of your loved ones is living with cancer.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
The goal is to “make customizable stem cell products that could be adapted to any particular patient.”
Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
In a recent study, Dana-Farber scientists and others uncovered a key part of why some patients eventually become resistant to Venclexta.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Quincy’s treatment would take him and his family to the frontier of using precision medicine to find a drug to save the infant’s life.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.